Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5750 |
Name | endometrial serous adenocarcinoma |
Definition | A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer uterine corpus cancer endometrial serous adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E542K | Copanlisib | endometrial serous adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01367002 | Phase II | Trastuzumab Carboplatin + Paclitaxel | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | Completed | USA | 0 |
NCT02491099 | Phase II | Afatinib | A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (Afatinib) | Recruiting | USA | 0 |
NCT03660826 | Phase II | Olaparib Cediranib + Olaparib | Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03668340 | Phase II | Adavosertib | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT03694262 | Phase II | Atezolizumab + Bevacizumab + Rucaparib | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) | Completed | USA | 0 |
NCT03694834 | Phase I | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer | Terminated | USA | 0 |
NCT03832361 | Phase II | Mirvetuximab Soravtansine | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer | Recruiting | USA | 0 |
NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 3 |
NCT04080284 | Phase II | Niraparib | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | Recruiting | USA | 0 |
NCT04159155 | Phase II | Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP) | Recruiting | CAN | 0 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Unknown status | USA | 0 |
NCT04293094 | Phase I | AMG 650 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Completed | USA | ITA | ESP | CAN | BEL | AUS | 1 |
NCT04585958 | Phase I | Olaparib + Trastuzumab deruxtecan | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer | Suspended | USA | 0 |
NCT04590248 | Phase II | Adavosertib | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO) | Completed | USA | ITA | FRA | ESP | CAN | 0 |
NCT04719273 | Phase II | Anastrozole + Onapristone | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Active, not recruiting | USA | 0 |
NCT04814108 | Phase II | ZN-c3 | A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Recruiting | USA | CAN | AUS | 1 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT05256225 | Phase II | Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Recruiting | USA | 1 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05542407 | Phase I | Atezolizumab + ONC201 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Recruiting | USA | 0 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT05611931 | Phase III | Selinexor | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) | Recruiting | USA | SVK | ITA | ISR | IRL | HUN | GRC | ESP | DEU | CZE | CAN | BEL | AUS | 1 |
NCT05826015 | Phase I | AVB-S6-500 AVB-S6-500 + Paclitaxel | AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Withdrawn | 0 | |
NCT05870761 | Phase II | Dostarlimab-gxly + Niraparib | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | Recruiting | USA | 0 |
NCT05920798 | Phase Ib/II | FR alpha peptide vaccine + Pembrolizumab | A Study of FRaDCs for Ovarian Cancer | Recruiting | USA | 0 |
NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06369155 | Phase II | ZN-c3 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | Not yet recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |